Fig. 1

Uptake and degradation of extracellular amyloid β (Aβ) aggregates by SNK01. A-E Intracellular levels of Aβ aggregates in SNK01 and HMC3 cells were analyzed by Western blot analysis. A SNK01 cells were treated with varying concentrations of Aβ aggregates for 1 h and harvested. B SNK01 cells were treated with 5 µM of Aβ aggregates and harvested at 1, 3, 6, 9, and 24 h after treatment. C SNK01 cells were treated with 5 µM Aβ aggregates for 1 h and washed 3 times with PBS. Then SNK01 cells were incubated in fresh medium for up to 48 h and harvested at 1, 3, 6, 24, and 48 h after wash. D HMC3 cells were treated with 5 µM of Aβ aggregates for 1, 3, and 6 h. N.C: negative control without treatment with Aβ aggregates. E HMC3 cells were treated with 5 µM Aβ aggregates for 1 h and washed 3 times with PBS. Then cells were incubated further in fresh medium for up to 48 h and harvested at 1, 3, 6, 24, and 48 h after wash. F-J SNK01 cells were incubated with 5 µM of Aβ aggregates for 24, 48, and 72 h and analyzed for viability (F), cytotoxicity at 72-h after treatment (G), degranulation (H), intracellular expression of IFN-γ and TNF-α (I), and surface expression of various activating NK receptors at 72-h after treatment (J)